Short Term Scrips Recommmendation

Buy NTPC - Target 195 - Within 2 Months
Buy Sunil Hitech Engineers - Target 228 - Within 1 Month

Long Term Scrips

Buy Siemens - Target 750 - One Year
Buy TCS - Target 1250 - One Year

For comments and queries write to vikyshan@gmail.com

Infosys plans to cut U.S. dependence to 40 pct

Infosys Technologies plans to cut dependence on the United States to about 40 percent from more than 60 percent now, its chief executive said, as a slowdown in the world's largest economy hits outsourcing deals.

Infosys, which got 63 percent of its revenue from the United States in the June quarter, planned to boost contribution from Europe to 40 percent from 27 percent, while other markets would account for the remaining 20 percent, CEO S. Gopalakrishnan said.

"We will continuously evolve and change," Gopalakrishnan told Reuters in an interview on Friday.

"It's also driven by realization that emerging markets are contributing more to the global GDP growth, that's where the growth is faster." He declined to set a time-frame for this, saying: "It's not that you need to do it tomorrow, that you have hit a wall."

Earlier this month, Infosys, India's second-largest software services exporter, beat forecasts with a 21 percent rise in quarterly profit but warned of challenging times ahead as its major Western clients battle weakening economies.

Indian outsourcing firms such as Infosys and its bigger rival Tata Consultancy Services are rapidly expanding to Europe, Asia, the Middle East and Latin America to cut their dependence on the United States.

Gopalakrishnan said Nasdaq-listed Infosys was also focusing on markets such as Japan, India, Australia, China, the Middle East, Canada and Latin America due to growing technology spending in these markets.

"These are new growth engines for us. We are investing in those markets and adding sales capacities," he said. "Some momentum is being built and if it's sustained over time I think this will have a positive impact on the company."

Despite mounting turmoil in the global financial industry, Infosys is not seeing downward pressure on prices that it charges its clients, but Gopalakrishnan said it doesn't expect an increase in billing rates either.

Infosys, which develops applications, designs supply chains and offers back-office services, counts ABN AMRO, Goldman Sachs and Philips Electronics among its more than 560 clients.

Gopalakrishnan, one of the seven founders of Infosys which was set up in 1981, expects the consulting business unit to break even in the current financial year to March 2009, as it taps more customers for this high margin service.

In the last financial year which ended in March, the consulting unit reported a loss of $13 million.

"It is a conscious choice for us to continue to invest in it," he said. "It is good business... It is a piece that is required if you want to be a full services company."

Shares in Infosys, which the market values at $21 billion, ended nearly 1 percent lower at 1,550.30 rupees in a Mumbai market which fell 3.4 percent.

Source : Sharekhan.com

State Bank Q1 net up 15.1 pct, beats forecast

State Bank of India, India's largest bank, posted a 15.1 percent rise in quarterly net profit on Saturday, beating forecasts, helped by its access to low-cost funds.

The state-run bank, which raised $4.1 billion in a rights issue in March, said its net profit in April-June, its fiscal first quarter, rose to 16.41 billion rupees ($388 million) from 14.26 billion rupees reported a year earlier.

A Reuters poll of analysts had forecast a 2.9 percent rise in March quarter earnings to 14.67 billion rupees.

State Bank, which has more than 10,000 branches across India and overseas, has the lowest cost of funds among the nation's lenders. The bulk of its funds come from savings bank deposits that cost about 3.5 percent in annual interest payments.

Shares in State Bank shares fell 31 percent in the June quarter, faring worse than the 14 percent drop in the main share index and a 23 percent slump in the banking sector index.

Source : Sharekhan.com

Short Term Scrips Recommendation - July 25

Buy Sail - Target 170 - Within 1 Month
Buy Engineers India - Target 650 - Within 1 Month

Write comments and queries to vikyshan@gmail.com

Intraday Tips - July 25

Buy MTNL - Target 111 - Stop Loss 93
Buy Torrent Pharma - Target 169 - Stop Loss 153

Write Comments and queries to vikyshan@gmail.com

Buy Zensar Technologies - Multibagger

Zensar Technologies - Target 250+ in One Year.

Zensar Technologies shot up to a high of Rs 132 after it reported an 85 per cent rise in net profit for the quarter to June.

At 3 pm, the company's shares rose 6.98 per cent to Rs 129.50 with a volume traded at 28099 against two-week average of 3945 shares.

The IT and BPO services provider posted a net profit of Rs 24.73 crore in the April-June quarter compared with Rs 133.5 crore in the previous year. Net sales stood at Rs 211.07 crore as against Rs 187.9 year ago.

Short Term Scrips Recommendation - July 24

Buy IVRCL - Target 355 - Within One Month
Buy Thermax - Target 455 - Within One Month

For comments and queries write to vikyshan@gmail.com

Short Term Scrips - July 22

Buy Maruthi Suzuki - Target 650 - Within 1 Month
Buy Sterlite Opticals - Target 220 - Within 1 Month

Results of Dr.Reddys, HDIL and Indian Bank Looks Impressive

Dr Reddy's Q1 net falls 26 pc

Indian drug maker Dr Reddy's Laboratories Ltd reported on Monday quarterly profit fell 26 per cent, worse than expectations, hit by its underperforming Germany-based Betapharm unit.

The Hyderabad-based firm, the only Indian drug maker listed in New York, said April-June consolidated net profit fell to 1.35 bn rupees ($32 mn) from 1.83 bn a year earlier.

A survey of seven brokerages had forecast net profit would at 1.58 bn rupees. Estimates ranged from 1.08 bn rupees to 2 bn rupees.

Betapharm, which Dr Reddy's bought in 2006 for $572 mn, has been a drag on earnings due to supply constraints and price falls.

Dr Reddy's is moving Betapharm's manufacturing operations to India and other manufacturers within Europe. Shares in Dr Reddy's, which the market values at $2.6 bn, rose 13.5 per cent during the June quarter, outperforming an eight percent rise in the healthcare index and 14 per cent drop in the benchmark index.

HDIL Q1 net up 56.86 pc at Rs 314 cr

Real estate major Housing Development and Infrastructure Ltd (HDIL) on Monday announced a net profit of Rs 317.93 crore for the first quarter of current fiscal year, a 56.86 per cent growth over the corresponding period a year ago.
The company had a net profit of Rs 202.68 crore for the quarter ended June 30, 2007, HDIL said in a filing to Bombay Stock Exchange.
The total revenue of the company rose to Rs 588.03 crore in the latest quarter, from Rs 445.84 crore in the year-ago period.
Meanwhile, the company further said its board of directors have received and reviewed the monitoring agency's report regarding the utilisation of its IPO proceeds.
Shares of the company were trading at Rs 441.60, up 2.38 per cent on Bombay Stock Exchange.

Indian Bank Q1 net up at Rs 217.62 cr

Public sector lender Indian Bank on saturday announced a net profit of Rs 217.62 crore for the quarter ended June 30, 2008, a 2.64 per cent growth over the corresponding quarter previous year.

The company had posted a net profit of Rs 212.09 crore in the quarter ended June 30, 2007, Indian Bank said in a filing to the Bombay Stock Exchange.

Total income of the company rose to Rs 1,744.99 crore for the quarter ended June 30, 2008, from Rs 1,376.74 crore last year.

FIIs shun index stocks, trim holding in half of BSE-100

Investment gurus always aver that it is not a good time to buy a market when too many global investors are excited about it.

By that logic, foreign investors stampeding out of a market could be a sign that it is time to start putting in your money there. The bearish outlook of foreign institutional investors on Indian equities is clearly reflected in the shareholding pattern of key companies.

Based on latest available data, FII holdings in 42 out of 71 BSE-100 stocks have fallen during the quarter-ended June. FIIs have trimmed their stakes in Sensex companies such as ACC, L&T, HDFC, ICICI Bank, BHEL, Bharti Airtel to name a few. FII holding in ACC (Sensex weightage: 0.67%) dipped by almost 6% during the quarter, in L&T (Sensex weightage: 6.88%) by 2.44%, in HDFC (Sensex weightage: 4.79%)by 1.53% and ICICI Bank (Sensex weightage: 6.66%) by 1.45%.

FIIs net sold Rs 14,969 crore or $3.7 billion worth of Indian shares during the April-June quarter. Net outflows of Rs 10,577 crore in June was the second highest in a single month this year. In January, foreign funds had pulled out Rs 17,226 crore. “The pace of FII outflows will slow down once macro fundamentals stabilise,” said the head of research of the Indian arm of a US-based brokerage.

A recent Merrill Lynch report says that rising inflation in emerging markets makes them more vulnerable to monetary tightening and slowing domestic demand. “The best combination for emerging market equities is rising commodity prices and falling EM interest rates; the worst is falling commodity prices and rising EM interest rates. Weaker global growth and higher inflation in emerging markets is raising the risk of the latter, which is why asset allocators have become much more cautious on emerging markets,” said Michael Hartnett, chief global emerging markets equity strategist at Merrill Lynch.

Another US-based brokerage, Citigroup Global Markets, has forecast an average 20% increase in earnings of Sensex companies this financial year. “Look for quality over quantity. Numbers will likely count a little less this time. Watch for profit and growth guidance, interest and cost pressures, order books and cancellations, funding and capital markets sensitivity, and body language,” said Citi in its recent report. Investment strategist Gul Tekchandani maintains that there is a higher probability of the market rising in the next 6 months, rather than falling. “It has been noticed historically whenever MSCI price-earning ratios in the past have come down to around 13, the markets see a bounceback of over 10%,” he said commenting on market trend.

Mr Tekchandani points out that select India-dedicated long only foreign funds have turned buyers at these levels. This is borne out by the rise in FII holdings in some Sensex companies. HDFC Bank, Infosys, Tata Steel, TCS and RCom were amongst those which saw a gain in FII holdings. HDFC Bank with a weightage of 3.76% in the Sensex, has seen FII shareholding go up by more than 2%. Other companies outside of the Sensex universe which witnessed a gain in FII shareholding include that of Cairn India(6.99%), JSW Steel (2.91%), Aditya Birla Nuvo (2.51%) and Idea Cellular (3.57%).

Short Term Scrips Recommendation - July 21

Buy NTPC - Target 195 - Within 3 Months
Buy Infosys - Target 1800 - Within 3 Months

Write comments to vikyshan@gmail.com

Short Term Scrips recommendation

Buy Bharat Forge - Target 269 - Within 1 Month
Buy Deccan Chronicle Holdings - Target 119 - Within 1 Month

For comments and Queries write to vikyshan@gmail.com

Inflation rises marginally to 11.91%

The annual Wholesale Price Index-based inflation moved up to 11.91 per cent for the week ended July 5, with a slowdown in the primary articles inflation ensuring that the rise was only marginally higher than the 11.89 per cent reported for the previous week.

During the latest week, inflation in manufactured products rose 10.79 per cent on a year-on-year basis, up from 10.64 per cent during the previous reported week, with dairy products up 11 per cent, edible oils rising 18 per cent, fertilisers up 10 per cent and iron and steel surging 35 per cent.

Inflation in the fuels group inched up further to 16.94 per cent during the latest week, from 16.27 per cent in the previous week, on account of a 27 per cent jump in inflation in the mineral oils category and a 10 per cent spike in the coal group.
primary articles

Inflation in primary articles, however, bucked the trend and came down by 92 basis points to 9.92 per cent during the latest week, with inflation in the vegetables, pulses, and the eggs, meat and fish categories showing a decline.

Responding to the latest figures, the Finance Ministry on Thursday declared that inflation has “stabilised” on week-on-week basis. “The rate of inflation for the week ending July 5, 2008 stands at 11.91 per cent, very marginally higher than the rate of 11.89 per cent reported last week... Inflation, on a week-on-week basis, has stabilised,” the Finance Ministry said in a statement released along with official figures on inflation.

The statement said annual inflation rate for the group of 30 essential commodities has declined to 5.74 per cent during the week ending July 5 from 5.98 per cent reported last week.

Short Term Target Scrips

Buy Hanung Toys - Target 200 - Within 3 Months
Buy Page Industries - Target 520 - Within 3 Months

Intraday Tip - July 17

Buy Ranbaxy - Target 484 - Stop Loss 451
Short Sell GMDC - Target 211 - Stop Loss 236

Deal with Daiichi Sankyo well on track, says Ranbaxy chief

Ranbaxy Laboratories on Wednesday said that the probe by the US Department of Justice (DoJ) will not jeopardise its deal with Japanese pharmaceutical company Daiichi Sankyo.

“The Daiichi Sankyo deal is very much on track. There’s absolutely no change in any of the terms or conditions or pricing of the deal. There is no exit clause in the agreement with Daiichi Sankyo,” Mr Malvinder Mohan Singh, Chairman and Managing Director, Ranbaxy, said.

In June this year, Daiichi Sankyo announced that it will buy out 34.8 per cent stake held by the Singh family in Ranbaxy and make an open offer, starting August 8 and closing on August 27, for acquiring an additional 20-per cent stake in the Indian drug major. “Daiichi Sankyo, as a part of the due diligence, was completely aware of this issue that’s open with the US Food and Drug Administration (USFDA),” Mr Singh added.

The company also blamed its rivals for trying to bring down its share price after news about the US investigation broke out earlier this week. Ranbaxy’s shares dipped 23 per cent over the past two days to close at Rs 409.25 on Tuesday after the US Government said it was probing into whether the Indian drug maker had falsified data and sold sub-standard generic drugs.

Hitting out at rival companies, Mr Singh said a multinational and a leading Indian company were trying to bring down Ranbaxy’s share price by spreading confusion and speculation in the wake of the motion filed in the US.

“There has been speculation in the market due to lack of understanding and we have information that a multinational and a leading Indian company are working in concert to bring our share price down. I have a clear sense of what is happening. People are trying to create confusion and obviously somebody is trying to bring our price down so that they buy Ranbaxy’s share at a lower price,” Mr Singh said without naming the companies.

However, on Wednesday, the company’s shares rebounded with a 15 per cent increase to close at Rs 470.70 after Mr Singh told newspersons that the deal with Daiichi Sankyo was on track. Mr Singh said that the company was confident of resolving the issue with the US authorities. “This (the motion filed by the DoJ) is to seek additional information. There is nothing beyond that. We intend to supply all the information being sought by them within a month. It’s our understanding that this motion will be recalled once that information is made available to them. Our business in America carries on as it was,” he said. Last year about 25 per cent of Ranbaxy’s revenue’s came from the US.

Earlier, the US department filed a motion against Ranbaxy alleging false and fabricated information had been submitted to the Food and Drug Administration. The motion added that allegations from reliable sources and supporting documents indicated a pattern of systemic fraudulent conduct by the Indian drug maker.


On Monday, Ranbaxy filed an eight-page response in the US district court for the district of Maryland, saying, “We are in the process of producing requested supporting documentation for our Abbreviated New Drug Applications to DoJ and believe that the requested documentation will demonstrate that no data manipulation fraud, or dishonesty occurred in those applications.”

Intraday Tip - July 16

Buy Tech Mahindra - Target 685 - Stop Loss 646
Buy Aurobindo Pharma - Target 290 - Stop Loss 268

write comments and queries to Vikyshan@gmail.com

Hot NSE BSE Recommendations - July 15

Free NSE|BSE Stock Tips

Buy GMDC - Target 280 - Short Term Target - Stop Loss 190
Buy Gujarat NRE Coke - Target 126 - Short Term Target - Stop Loss 81

Write comments and queries to vikyshan@gmail.com

Hot NSE BSE Recommendations - July 11

Free Indian share Tips

Buy Hind Rectifiers - Target 153 - within 15 days - Stop Loss 108
Buy Infosys - Target 2000 - Within 3 Months - Stop Loss 1695

Write comments and queries to vikyshan@gmail.com

Hot NSE BSE Recommendations - July 10

Indian Stock Market Tips

Buy Siemens - Target 520 - Short Term Target - Stop Loss 433
Buy India Cements - Target 161 - Short Term Target - Stop Loss 119

For comments and queries write to vikyshan@gmail.com

Hot NSE BSE Recommendations - July 8

Buy Pyramid Saimara on dips - Target 250 - One year
Buy Wipro - Target 550 - One year

For Comments and queries write to vikyshan@gmail.com

Hot NSE BSE Recommendations - July 8

Free Stock Market Tips

Buy Glenmark Pharma - Target 638 - Short Term Target - Stop Loss 581
Buy ITC - Target 190 - Short Term Target - Stop Loss 158

Write comments and queries to vikyshan@gmail.com

Hot NSE BSE Recommendations - July 4

Free BSE|NSE Stock Tips

The market seems to move upwards now. So start buying good stocks.

Buy Cairn Ind - Target 278 - Short Term Target - Stop Loss 213
Buy Ranbaxy - Target 557 - Short Term Target - Stop Loss 472

write comments and queries to vikyshan@gmail.com

Hot NSE BSE Recommendations - July 2

The stock market is very volatile so buy A group shares for medium term to get good profits. The stock market will rise from mid july.

Buy TCS - Target 940 - Within 1 Year
Buy Maruti - Target 700 - Within 1 Year
Buy Infosys - Target 1980 - Within 1 Year

For comments and queries write to vikyshan@gmail.com

Hot NSE BSE Recommendations - July 1

Free NSE|BSE Stock Tips

Buy ITC Ltd - Target 208 - Short Term Target - Stop Loss 162
Buy HInd Rectifiers - Target 160 - Short Term Target - Stop Loss 111

Write comments and queries to vikyshan@gmail.com